9-(2-Hydroxyethyl)-β-carbolin | 22946-01-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 9-(2-Hydroxyethyl)-β-carbolin
• 英文别名: 2-β-carbolin-9-yl-ethanol；2-(9H-beta-Carbolin-9-yl)ethan-1-ol；2-pyrido[3,4-b]indol-9-ylethanol
• CAS: 22946-01-6
• 化学式: C₁₃H₁₂N₂O
• 分子量: 212.251
• InChiKey: MPLKMQHZGKUTGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  9-(2-Hydroxyethyl)-β-carbolin 在 sodium hydroxide 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 19.0h， 生成 (S)-3-(4-(2-(Betacarbolin-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid
  参考文献：
  名称：

  Novel Tricyclic-α-alkyloxyphenylpropionic Acids:  Dual PPARα/γ Agonists with Hypolipidemic and Antidiabetic Activity

  摘要：

  Synthesis and structure-activity relationships of tricyclic alpha-ethoxy-phenylpropionic acid derivatives guided by in vitro PPARalpha and PPARgamma transactivation data and computer modeling led to the identification of the novel carbazole analogue, 3q, with dual PPARalpha (EC50 = 0.36 muM) and PPARgamma (EC50 = 0.17 muM) activity in vitro. Ten days treatment of db/db mice with 3q improved the insulin sensitivity, as measured by OGTT, better than that seen with both pioglitazone and rosiglitazone treatment, suggesting in vivo PPARgamma activity. Likewise, 3q lowered plasma triglycerides and cholesterol in high cholesterol fed rats after 4 days treatment, indicating in vivo PPARalpha activity. Investigations of the pharmacokinetics of selected compounds suggested that extended drug exposure improved the in vivo activity of in vitro active compounds.

  DOI：

  10.1021/jm010964g
• 作为产物：
  描述：

  9H-吡啶[3,4-b]吲哚 在 正丁基锂 作用下， 以 四氢呋喃 、 氮 为溶剂， 以660 mg (53%)的产率得到9-(2-Hydroxyethyl)-β-carbolin
  参考文献：
  名称：

  New compounds, their preparation and use

  摘要：

  本发明涉及一般式(I)的化合物。这些化合物在治疗和/或预防由核受体介导的疾病方面具有用途，特别是过氧化物酶体增殖激活受体（PPAR）。

  公开号：

  US20020010171A1

文献信息

• Novel compounds, their preparation and use
  申请人：——

  公开号：US20030055076A1

  公开（公告）日：2003-03-20

  Novel compounds of the general formula (I), the use of these compounds as medicaments, pharmaceuticaly compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR). The compounds exert their effects by modulating the PPAR&ggr; response in a partial agonist manner.

  本发明涉及一般式（I）的新化合物，这些化合物作为药物的用途，包括这些化合物的制药组合物和使用这些化合物和组合物的治疗方法。这些化合物可能在治疗和/或预防由核受体介导的疾病方面有用，特别是过氧化物酶体增殖物激活受体（PPAR）。这些化合物通过以部分激动剂方式调节PPAR&ggr;反应来发挥作用。
• PYRIDO[3,4-B]INDOLES AND METHODS OF USE
  申请人：HUNG David T.

  公开号：US20090270412A1

  公开（公告）日：2009-10-29

  This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[3,4-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及新的杂环化合物，可用于调节个体中的组胺受体。描述了吡啶并[3,4-b]吲哚类化合物，以及包含该化合物的药物组合物和使用该化合物进行各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• Compounds, their preparation and use
  申请人：Novo Nordisk A/S

  公开号：US06534517B2

  公开（公告）日：2003-03-18

  The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

  本发明涉及一般式(I)的化合物。这些化合物在治疗和/或预防由核受体介导的疾病方面有用，特别是过氧化物酶体增殖物激活受体（PPAR）。
• COMPOUNDS, THEIR PREPARATION AND USE
  申请人：NOVO NORDISK A/S

  公开号：EP1171438A1

  公开（公告）日：2002-01-16
• NOVEL VINYL N-(2-BENZOYLPHENYL)-L-TYROSINE DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC
  申请人：NOVO NORDISK A/S

  公开号：EP1414806A1

  公开（公告）日：2004-05-06